Lankenau Medical Center performs first minimally invasive procedure for aortic regurgitation in Philadelphia region
Clinical trial establishes Lankenau as one of the most comprehensive heart valve centers nationally by offering yet another alternative to open-heart surgery.
Wynnewood, PA — Lankenau Medical Center, part of Main Line Health, has performed the first minimally invasive catheter-based procedure to treat aortic regurgitation in the Philadelphia region.
A cardiac team led by Basel Ramlawi, MD, chief of cardiothoracic surgery at Main Line Health, conducted the procedure in May as part of the JenaValve ALIGN-AR trial using an experimental Trilogy™ heart valve system. The trial is the first use of a valve designed to treat aortic regurgitation through a minimally invasive procedure called transcatheter aortic valve replacement (TAVR).
Nick Amoroso, MD; Jeremy Lane, RN; Basel Ramlawi, MD, Eric Gnall, DO; Stanley Oliveira, RN;
Chris Torretti (JenaValve); Frank De La Huerta (JenaValve).
Lankenau Medical Center has used TAVR to treat patients with aortic stenosis for over 10 years and was one of the first U.S. medical centers selected to offer it after the FDA approved the treatment option.
Aortic regurgitation is a condition where the aortic valve does not close tightly and allows blood to leak back into the heart’s main pumping chamber. The leakage may prevent the heart from operating efficiently to deliver blood to the rest of the body. Symptoms may include fatigue and shortness of breath and tend to develop gradually over months or years. The ALIGN-AR trial is for patients with symptomatic, severe aortic regurgitation who are at high risk for open surgery. The trial, among other Lankenau innovations, allows the Lankenau heart team to offer treatment strategies for complex valve disease in a patient-tailored approach.
“We seek to treat our patients with the most effective, minimally invasive therapies available for their specific condition,” said Ramlawi, who also is co-director of the Lankenau Heart Institute and a professor for Lankenau Institute for Medical Research, which is Main Line Health’s research division and oversees clinical trials. “We bring unique and distinct capabilities to this effort, with a decade of experience treating patients suffering from aortic stenosis using TAVR.”
Lankenau heart surgeons are national leaders in teaching minimally invasive and catheter-based valve procedures. Lankenau has performed more than 2,100 TAVR procedures for various conditions since 2012, including more than 300 in 2022. It is among the top 10% of highest performing TAVR centers in the nation.
The JenaValve Trilogy™ has been approved for commercial use in Europe but is not approved in the United States and is currently being investigated in the ALIGN-AR trial.
Lankenau continues to be a national leader in minimally invasive heart surgery. It performs the highest percentage of robotically assisted coronary bypass procedures in the country. It also is a leader in mitral valve repair using the MitraClip™, a minimally invasive treatment for mitral valve regurgitation. The cardiac team performed its 300th MitraClip procedure last year.
This document uses words such as treatment, minimally invasive, and patient. Please remember the JenaValve ALIGN-AR is a research study and the use of these terms does not mean the use of the device has been found to be safe or effective for your condition.
About Lankenau Medical Center
Founded in 1860, Lankenau Medical Center is recognized among the top hospitals in the Philadelphia region for exceptional patient care. The hospital offers a comprehensive range of primary care, disease prevention, and specialized medical and surgical services, including cardiovascular care, cancer care, obstetrics and neonatology, pulmonology and thoracic care, gastroenterology and GI surgery, and orthopaedics. It also offers a level II trauma center.
A leader in medical education, Lankenau Medical Center trains a diverse group of residents and fellows participating in programs across multiple specialties. The hospital is also home to the Lankenau Institute for Medical Research, where groundbreaking research advances the detection, diagnosis and treatment of diseases and offers access to clinical trials. Lankenau Medical Center combines compassionate care with cutting-edge technology in a patient-centered environment.
About Lankenau Institute for Medical Research
Lankenau Institute for Medical Research (LIMR), part of Main Line Health, is a nonprofit biomedical research institute on the campus of Lankenau Medical Center celebrating its landmark 100th anniversary of scientific accomplishment in Fall 1927. LIMR's mission is to improve human health and well-being. Through its ACAPRENEURIAL™ organizational model, which integrates academic and entrepreneurial approaches, LIMR faculty and staff advance innovative strategies to address formidable medical challenges including cancer, cardiovascular disease, tissue regeneration, gastrointestinal disorders and autoimmune diseases such as rheumatoid arthritis. LIMR's principal investigators conduct basic, preclinical and clinical research, using their findings to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training the next generation of scientists and physicians.
About Main Line Health
Main Line Health® is a not-for-profit health system serving the greater Philadelphia region. The System comprises five hospitals, seven health centers, more than 160 outpatient and physician practice locations, over 14,500 employees and more than 2,200 employed and independent physicians and advanced practice providers.
Founded in 1985, Main Line Health includes four of the region’s most respected acute care hospitals — Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital — as well as Bryn Mawr Rehab Hospital, one of the nation’s premier facilities for rehabilitative medicine. The System also includes Mirmont Treatment Center, which provides treatment and support for substance use disorders; Main Line Health HomeCare & Hospice; Main Line HealthCare, its employed multispecialty physician network; Lankenau Institute for Medical Research, a leading biomedical research organization; and Main Line Health Centers offering primary and specialty care, lab, radiology and other outpatient services in Broomall, Collegeville, Concordville, Devon, Exton, King of Prussia and Newtown Square.
Main Line Health brings together physicians, advanced practice providers, nurses, researchers and other healthcare professionals across a broad network of inpatient, outpatient, home-based and community-based services. Through this integrated approach, the System delivers high-quality, comprehensive care across the continuum — from primary care and preventive services to complex specialty, surgical, trauma, emergency, rehabilitative, behavioral health, home care and hospice services — with a focus on making care accessible in the communities where people live and work.
Main Line Health also collaborates with leading clinical partners to expand access to specialized care. Through its affiliation with Children's Hospital of Philadelphia, pediatric care is provided at select Main Line Health locations, including neonatal intensive care units at its acute care hospitals and Bryn Mawr Hospital’s Inpatient Pediatric Unit and Emergency Department. Jefferson Health neurosurgeons and neurointerventionalists also provide 24/7 specialized care, including neurointervention and lifesaving stroke care.